Prestonian, Good analysis. Good to see someone who is thinking...

Prestonian,

Good analysis. Good to see someone who is thinking

Total dosed: 21
Completed: 2
Reached Mid-Point but not completed (90mg): 9
Early stages: 10

Of the two completed: we know one achieved a 66% reduction. This is a phenomenal result considering the patient was already on irbesartan. Again if there proteinuria was say 100 prior to irbesartan, then with it we would expect it to drop to 75 on average. A further 66% reduction takes it to 25! That's a 75% reduction from baseline for this patient. If I was that patient, I'd be bloody happy - because on standard of care- I was leaking three times as much protein into my urine before I started the study! The other patient does not seem to have achieved 50% or more as this was not stated. However, as discussed- BOTH have continued on the drug under TGA SAS. This strongly suggests that the second patient achieved a clinically significant, but not quite 50% or greater, reduction. If it were not clinically significant then their kidney specialist would not have continued them on the drug. Reading between the lines- you don't have to achieve a 50% or more reduction whilst already on irbesartan for your kidney specialist to keep you on the drug! 20% or more should do it!

So of the two completed patients- we have two clinically significant results that has altered the management of the patients, with one having an astronomical reduction! 2 out of 2.. I think that's close to 100%!

We then know that 2 others out of the 9 who have not completed but reached the midpoint of the study have also achieved a brilliant reduction , 50% or more. 2/9 or 22%. The other 7 could achieve a significant reduction by the end of the study. The other 7 perhaps have also achieved a clinically significant reduction which would encourage the doctor to continue them on SAS too. We will have to see.

The other 10 (those who haven't reached mid-point of the study) are far too early to analyse other than to say that they have at least tolerated part of the first dose level.

OK.. let's look at the 11 patients again who have either completed (2) or reached the mid point (9).

Completed:
1- 66%
2- ?20% -but we know they are continuing on the drug, so lets say 20% (because we know kidney specialists were prescribing dual RAS blockade to achieve a further 20-25% before they found out the side effects of the combination outweighed the benefit- let's not forget this.. we don't need 50% or more on irbesartan for clinicians to want to use it.. case in point- this second patient who is still taking it on SAS).

3- 50% (from data, could be more as they stated 50% or greater)
4- 50% (from data, could be more as they stated 50% or greater)
5- 11: let's assume 0% reduction by the end of study.

Then the average for these 11 (who haven't even all completed the study) would be: (66+20+50+50+0+0+0+0+0+0+0)/11 = 17%.

Once completed, if we assume the 5-11 patients had an average of 10% reduction (not inconceivable given the results of the other 3 , possibly 4 known patients) then the overall average would be:

(66+20+50+50+10+10+10+10+10+10+10)/11 = 23%.

Let's now look at Chemocentryx. US NASDAQ listed biotech who adde a CCR2 antagonist to either ARB or ACE inhibitor similar to Dimerix.

"ChemoCentryx said a reduction in proteinuria (protein levels in the kidneys) of 20% or more would define success for CCX140 in the interim analysis...

CCX140 was unable to hit that 20% proteinuria reduction target.

ChemoCentryx said certain subsets of patients -- defined before the study began -- did show reductions in proteinuria greater than 30% following treatment with CCX140 compared to placebo. "

DMX-200 achieved greater than 50% reduction already in more patients than have completed the study 3/2!! Chemocentryx were happy with a 20% reduction - they didn't get it. They showcased that some achieved over 30%, DMX-200 had over 50%.

There is a lot to like about these results guys.. Remember, the CKD market is huge!

I think the company needs to start educating the market about what these early results mean and the potential the DMX-200 program has. at $16M market cap- I can hardly believe it.. Buy buy.